Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
The Globe and Mail

AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion

AbbVie has completed a Phase 1 study titled “A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Subcutaneous Administration With On-Body Injector ...
Nasdaq

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

NORTH CHICAGO, Ill., March 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating ...
Medical Xpress

High-dose risankizumab trial tests staying power against psoriasis

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired higher-than-approved doses of risankizumab with extended follow-up and ...